Canadian company B-Temia, Inc. and French company Sagem (Safran) today announced the signature of a technological and business development agreement concerning a new-generation of exoskeletons for industrial and military applications.
Exoskeletons are bio-mechanical and electronic structures worn on the body to assist and enhance people's movements, or to restore mobility.
According to the terms of this agreement, Sagem and B-Temia will jointly develop and market new-generation exoskeletons. Sagem will contribute its long experience in the integration of complex systems, its innovative actuators and stabilization technologies. B-Temia, an exoskeleton technology leader, will contribute its experience in human robotics and artificial intelligence, based on its proprietary "Dermoskeleton™" technology, already in production for the healthcare sector.
" B-Temia is very proud of this partnership with Sagem, focused on the development and production of our dermoskeleton products. This agreement confirms our company's technology leadership business value, and the credibility of our work addressing increased human mobility needs in both industrial and defense applications ," said Stéphane Bédard, President and CEO of B-Temia.
Martin Sion, Chief Executive Officer of Sagem, added, " Our collaboration with B-Temia will enable us to sustain new R&D work on exoskeletons. For Sagem, this is a very promising technology for industrial and military applications. In particular, our collaboration spotlights the dynamic mindset that Sagem seeks to deploy in the application of innovative dual technologies in conjunction with both startups and major corporations ."
Source: Safran S.A. (Paris: SAF.PA)
Date: Nov 9, 2015